TAK-875 improves glycemic control in diabetic patients
TAK-875 is a selective agonist of GPR40, one of the GPCRs that are expressed in pancreatic islet cells. The Phase 2 trial is a randomized double-blind placebo- and
Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Therapeutics for a total deal value of $125m.
The CSL Behring rFVIII, called rVIII-SingleChain, is being studied for the treatment of hemophilia A. The open-label, multicenter trial examines the crossover safety, efficacy and pharmacokinetics of recombinant